Personalis (NASDAQ:PSNL) Shares Up 13.5% – Here’s What Happened

Posted by Stanley Muller on May 18th, 2026

Personalis, Inc. (NASDAQ:PSNL – Get Free Report)’s stock price rose 13.5% on Monday . The stock traded as high as $6.88 and last traded at $7.2180. Approximately 332,325 shares changed hands during trading, a decline of 80% from the average daily volume of 1,650,960 shares. The stock had previously closed at $6.36.

Analyst Upgrades and Downgrades

PSNL has been the subject of a number of research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. Guggenheim upped their target price on Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a report on Monday, January 26th. Needham & Company LLC raised their price target on shares of Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Wall Street Zen downgraded shares of Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, BTIG Research cut their target price on shares of Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $11.00.

View Our Latest Analysis on PSNL

Personalis Price Performance

The business has a fifty day moving average of $6.61 and a 200 day moving average of $8.09. The stock has a market cap of $698.59 million, a price-to-earnings ratio of -6.55 and a beta of 1.96.

Personalis (NASDAQ:PSNL – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. The business had revenue of $15.47 million for the quarter, compared to the consensus estimate of $14.49 million. On average, analysts expect that Personalis, Inc. will post -1.06 EPS for the current year.

Institutional Trading of Personalis

Institutional investors and hedge funds have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd increased its holdings in shares of Personalis by 76.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after acquiring an additional 1,479 shares during the last quarter. Deutsche Bank AG lifted its holdings in Personalis by 4.5% in the 4th quarter. Deutsche Bank AG now owns 38,827 shares of the company’s stock worth $309,000 after purchasing an additional 1,655 shares during the last quarter. Royal Bank of Canada boosted its position in Personalis by 3.2% during the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after purchasing an additional 2,395 shares during the period. Howland Capital Management LLC boosted its position in Personalis by 0.9% during the second quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock worth $1,872,000 after purchasing an additional 2,500 shares during the period. Finally, Intech Investment Management LLC grew its holdings in Personalis by 23.4% during the fourth quarter. Intech Investment Management LLC now owns 20,342 shares of the company’s stock valued at $162,000 after purchasing an additional 3,851 shares during the last quarter. Institutional investors and hedge funds own 61.91% of the company’s stock.

About Personalis

(Get Free Report)

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.